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ABSTRACT
Background. Diabetic nephropathy (DN) is one of the major
late complications of diabetes. Treatment aimed at slowing
down the progression of DN is available but methods for early
and deﬁnitive detection of DN progression are currently
lacking. The ‘Proteomic prediction and Renin angiotensin
aldosterone system Inhibition prevention Of early diabetic ne-
phRopathy In TYpe 2 diabetic patients with normoalbuminuria
trial’ (PRIORITY) aims to evaluate the early detection of DN in
patients with type 2 diabetes (T2D) using a urinary proteome-
based classiﬁer (CKD273).
O
R
IG
IN
A
L
A
R
T
IC
L
E
© The Author 2014. Published by Oxford University Press
on behalf of ERA-EDTA. All rights reserved.
1563
Methods. In this ancillary study of the recently initiated PRI-
ORITY trial we aimed to validate for the ﬁrst time the
CKD273 classiﬁer in a multicentre (9 different institutions
providing samples from 165 T2D patients) prospective setting.
In addition we also investigated the inﬂuence of sample con-
tainers, age and gender on the CKD273 classiﬁer.
Results. We observed a high consistency of the CKD273 clas-
siﬁcation scores across the different centres with areas under
the curves ranging from 0.95 to 1.00. The classiﬁer was inde-
pendent of age (range tested 16–89 years) and gender. Further-
more, the use of different urine storage containers did not
affect the classiﬁcation scores. Analysis of the distribution of
the individual peptides of the classiﬁer over the nine different
centres showed that fragments of blood-derived and extracel-
lular matrix proteins were the most consistently found.
Conclusion. We provide for the ﬁrst time validation of this
urinary proteome-based classiﬁer in a multicentre prospective
setting and show the suitability of the CKD273 classiﬁer to be
used in the PRIORITY trial.
Keywords: biomarkers, chronic kidney disease, diabetic
nephropathy, diagnosis, urine proteomics
INTRODUCTION
In the year 2008; around 347 million people worldwide were
suffering from diabetes mellitus, representing about 9.5% of
the adult population [1]. In addition, the total number of
people with diabetes mellitus is estimated to double by 2030
[2]. Improved treatment and disease management has reduced
mortality, further contributing to increasing prevalence.
Diabetic nephropathy (DN) is one of the major late compli-
cations of diabetes and is associated with substantial cardio-
vascular morbidity and mortality [3]. A number of large-scale
clinical studies have demonstrated nephroprotective effects
by interfering with the renin-angiotensin-aldosterone system
[4–6]. Although these treatments slow down the progression
of renal disease, they do not halt its development.
Currently, microalbuminuria (30–300 mg/24 h or 20–200
μg/min) is considered a key risk factor for development of
DN. However, the value of microalbuminuria as a predictor of
DN is questioned since it is not speciﬁc and is highly variable
[7, 8]. Furthermore, THE onset of DN in the absence of overt
albuminuria has been reported in up to 50% of type 1 diabetic
patients [9], indicating a lack of sensitivity. Reduction of the
estimated glomerular ﬁltration rate (eGFR) in the context of
diabetes is a clear indication of advanced DN, but at this late
stage of the disease, the success of treatment is severely compro-
mised by irreversible structural damage [6]. Thus, microalbumi-
nuria lacks sensitivity/speciﬁcity and a signiﬁcant reduction of
eGFR is a late sign of DN.
We have previously established a urinary peptide-based clas-
siﬁer composed of 273 different urinary peptides termed
‘CKD273’, which detects with high sensitivity and speciﬁcity
chronic kidney disease (CKD) in patients with different disease
aetiologies [10]. In small-scale studies, this classiﬁer predicted
the progression from normoalbuminuria to macroalbuminuria
in diabetic patients [11, 12], as well as progression of CKD in pa-
tients with renal disease originating from different aetiologies
[13]. CKD273 was superior to urinary albumin in predicting
DN, and also signiﬁcantly improved prognosis based on current-
ly used classical risk factors [11].
The performance of CKD273 suggests clinical use of the
classiﬁer in early detection and prediction of progression of
CKD. Evaluation of CKD273 for selection of diabetic patients
that will beneﬁt from a low dose of aldosterone treatment in
combination with ACEi or ARB blockade is the aim of the re-
cently initiated multicentre interventional trial ‘Proteomic pre-
diction and Renin angiotensin aldosterone system Inhibition
prevention Of early diabetic nephRopathy In TYpe 2 diabetic
patients with normoalbuminuria’ (the PRIORITY trial, www.
eu-priority.org). In PRIORITY, n = 3280 patients with type 2
diabetes (T2D) will be assessed using the CKD273 classiﬁer to
detect individuals at ‘high risk’ of developing DN. This subset
of patients will be randomized to receive low-dose spironolac-
tone (25 mg/d) or placebo and followed up to assess time to
onset of DN. If positive, the study will demonstrate the value
of proteomics in guiding early targeted therapy with spirono-
lactone in T2D.
In the present ancillary study, we assessed the ability of
CKD273 to detect DN in prospectively collected urine samples
from a total of 165 T2D patients originating from 9 different
PRIORITY clinical centres.
SUBJECTS AND METHODS
Sample and patient characteristics
Urine samples were prospectively collected in nine different
centres (Table 1). Patients were considered to have DN upon
displaying macroalbuminuria and/or eGFR <45 mL/min/1.73 m2
(case). Diabetic patients without signs of DN (normoalbumi-
nuria and eGFR >60 mL/min/1.73 m2) were used as controls.
A mean of 18 (range 12–23) samples from each centre fulﬁlled
these criteria and could be included for this study. Patient
characteristics are given in Table 1. eGFR was estimated using
the ‘Modiﬁcation of Diet in Renal Disease’ (MDRD) formula
[14]. None of the included patients was in a regular mainten-
ance dialysis programme. The second morning urine was pre-
ferred and stored at −20°C in Urine-Monovette® (SARSTEDT
AG & Co, Nümbrecht, Germany). In addition, 19 urine
samples were collected at the Steno Diabetes Center to deter-
mine the effect of the use of different storage containers on the
urinary proteome pattern. After collection the samples were
transferred into either Nunc® CryoTubes® (Sigma-Aldrich Co.
LLC., St. Louis, MO, USA) or Urine-Monovette® (SARSTEDT
AG & Co, Nümbrecht, Germany) containers.
Sample preparation
The urine samples were prepared as described previously in
detail [15, 16]. Samples were thawed immediately before use.
A volume of 0.7 mL was diluted with 0.7 mL 2 M urea, 10 mM
NH4OH and 0.02% sodium dodecyl sulphate. To remove
high-molecular weight polypeptides, samples were ﬁltered
using Centrisart ultracentrifugation ﬁlter devices (20 kDa
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molecular weight cut-off; Sartorius, Goettingen, Germany)
at 3000 g until 1.1 mL of ﬁltrate was obtained. The ﬁltrate was
desalted with a PD-10 column (GE Healthcare, Uppsala,
Sweden) equilibrated in 0.01% NH4OH in HPLC-grade water.
The prepared samples were lyophilized and stored at 4°C.
Shortly before capillary electrophoresis coupled to mass spec-
trometry (CE/MS) analysis, lyophilisates were resuspended in
HPLC-grade water (Merck KGaA, Darmstadt, Germany).
CE/MS analysis and data processing
CE/MS analysis and data processing was performed as de-
scribed [10, 17], using a P/ACE MDQ capillary electrophoresis
system (Beckman Coulter, Fullerton, CA, USA) online coupled
to a micro-TOF MS (Bruker Daltonic, Bremen, Germany).
The accuracy, precision, selectivity, sensitivity, reproducibility
and stability of the analytical method are described in detail
elsewhere [10, 18]. Mass spectral ion signals representing iden-
tical molecules at different charge states were deconvoluted
into single masses using the MosaiquesVisu software [19]. To
achieve high mass accuracy, deconvoluted TOF mass signals
were calibrated based on FT-ICR-derived accurate masses
(mass deviation of 1 ppm) as described previously [20]. In
parallel, CE retention time by local regression and signal in-
tensities using internal standards were normalized as previous-
ly described [16]. All detected mass signals of peptides were
deposited, matched and annotated in a Microsoft SQL data-
base [20, 21].
Sample classiﬁcation and statistical analysis
For classiﬁcation of CKD versus non-CKD, the MosaClus-
ter software and the previously deﬁned CKD273 classiﬁer was
used [10].
Sensitivity and speciﬁcity of the previously deﬁned biomarker
models, and 95% conﬁdence intervals (95% CI) were calculated
using receiver operating characteristic (ROC) plots (MedCalc
version 8.1.1.0, MedCalc Software, Ostend, Belgium, www.
medcalc.be) [22]. The comparison of areas under independent
ROC curves was also done using the MedCalc software. For ana-
lysis of differences in individual biomarkers between cases and
controls, we used the non-parametric Wilcoxon test (R-based
statistic software, version 2.15.3). The classiﬁcation scores of the
19 samples stored in two different containers were compared
using a paired Wilcoxon test (MedCalc Software, Ostend
Belgium, www.medcalc.be).
RESULTS
Patients and samples
A total of 165 randomly collected urine samples from T2D
diabetic patients were prospectively collected in 9 centres
(Table 1) participating in the recently initiated PRIORITY study.
Eighty-seven patients with T2D had existing DN at baseline
while 78 were without DN (Table 1). Urinary albumin values and
eGFR values are shown in Table 1 by centre. For follow-up, some
centres measured urinary albumin (mg/L or mg/24 h) while
others measured the albumin/creatinine ratio or proteinuria
(Table 1). All samples were analysed using CE/MS and scoredTa
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using the CKD273 classiﬁer [10]. The individual classiﬁcation
scores are listed in Supplementary Table S1. Combined abun-
dance of all detected peptides and of the 273 CKD biomarkers
are shown in Figure 1. A clear difference in the abundance of a
large number of the 273 peptides of CKD273 can be observed
between T2D patients with and without DN (Figure 1C and D).
As CKD273 was initially deﬁned in a gender-balanced
cohort [10], we studied the effect of gender and age on the
classiﬁcation score. An age bias was observed in one of the
nine centres (Table 1, centre 9). Logistic regression was used to
investigate if patient age and gender contributed to the prote-
ome classiﬁer-based prediction of the diagnosis. Samples for
which no data on age were available (Table 1, centre 4, 6, 7)
were excluded from these analyses. No signiﬁcant contribution
of age and gender to the score was observed (P = 0.269 for age
and P = 0.312 for gender).
Inﬂuence of sample storage
To assess the possible effect of different containers for
urine collection on the classiﬁcation scores obtained with the
CKD273 classiﬁer, freshly collected samples (n = 19) were
stored in two different containers at −20°C: Nunc® Cryo-
Tubes® and Urine-Monovette® and shipped on dry ice. Both
replicates were analysed using CE/MS and classiﬁed using
the CKD273 classiﬁer. No signiﬁcant difference in CKD273
classiﬁcation was detected between samples from the two dif-
ferent storage containers (P = 0.623, paired Wilcoxon test).
Multicentre validation of CKD273 to detect DN
in T2D patients
The classiﬁcation scores of T2D patients were analysed
using receiver operation curve (ROC) statistics (Table 1) for
each individual centre. This resulted in AUC values for the in-
dividual centres ranging between 0.9 and 1.0. Comparison of
areas under independent ROC curves did not show signiﬁcant
differences between the individual AUC values. Figure 2A
shows these scores in the form of box and whisker plots for all
T2D patients with and without DN. As previously described
[10], a sample with a CKD273 score lower than 0.343 indicates
absence of DN, while a score above 0.343 indicates presence of
DN. When combining all 165 samples of the 9 centres the clas-
siﬁcation resulted in AUC of 0.95 (95% CI: 0.90–0.98)
F IGURE 1 : Compiled urinary protein proﬁles. (A) All peptides detected in the combined T2D cohort with DN and (B) without DN.
(C) The 273 CKD biomarkers in the combined T2D cohort with and (D) without DN. Normalized molecular weight (800–20 000 Da) in
logarithmic scale is plotted against normalized migration time (18–45 min). The mean signal intensity of polypeptides is given as peak height.
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(Figure 2B) with 18 of the 165 patients ‘misclassiﬁed’ in rela-
tion to standard clinical deﬁnitions.
In addition, we investigated whether the regulation of the indi-
vidual biomarkers in the different centres is similar to the regula-
tion initially described in Good et al. [10]. Using the non-
parametric Wilcoxon test, we investigated the distribution of the
individual 273 CKD biomarkers between the DN group and the
control group in each centre, and compared the distribution to
the one described in Good et al. [10]. Due to the low number of
samples in the individual centres, a P-value of 0.1 was used as the
cut-off. Two hundred and seven of the 273 CKD markers (76%)
could be veriﬁed in a minimum of one of the nine centres. These
207 markers are listed in Supplementary Table S2. This set of bio-
markers included 94 collagen alpha-1 (I), 37 collagen alpha-1
(III), 18 alpha-1-antitrypsin, 10 uromodulin, 9 collagen alpha-2
(I), 7 serum albumin, 4 ﬁbrinogen alpha, 3 polymeric-immuno-
globulin receptor, 3 alpha-2-HS-glycoprotein and 2 osteopontin,
sodium/potassium-transporting ATPase gamma and transthyre-
tin fragments.
To increase statistical power, we combined the data of T2D pa-
tients (n = 165) from all centres and investigated the distribution
of the 273 biomarkers in this combined cohort. Because of the
large number of samples used for this analysis, a P-value of 0.05
was used as signiﬁcance threshold. When examining the 100
most signiﬁcant biomarkers in the CKD273 classiﬁer (based on
the Good et al. [10], P-value <0.0001 in the training cohort and
the lowest P-values in the validation cohort), 67 out of those 100
peptides could be veriﬁed in the current study (Supplementary
Table S3, Figure 3). These were alpha-1-antitrypsin, serum
albumin, transthyretin, alpha-2-HS-glycoprotein, polymeric-
immunoglobulin receptor sodium/potassium-transporting
ATPase gamma and uromodulin fragments, as well as fragments
of collagen alpha-1 (I), alpha-1 (III) and collagen alpha-2 (I).
DISCUSSION
In the present ancillary study of PRIORITY, we observed a
high consistency of the CKD273 classiﬁcation scores across
centres, with areas under the curve (AUCs) for the separation
between patients with and without DN ranging from 0.9 to
1.0. Moreover, absence of an effect of gender and age on the
accuracy of the classiﬁer and absence of effects due to different
urine storage containers were established. These results
support the feasibility of using CKD273 routinely in a multi-
centre setting for the detection of DN in T2D patients.
In PRIORITY, as in any study using a proteomics approach,
reproducible results are essential for successful implementa-
tion. Numerous issues need to be considered in applying
proteome analysis to assess disease state, progression or re-
sponse to drug treatment in the clinic [23, 24].
One of the most relevant aspects is validation of the bio-
marker model in independent cohorts [25]. Validation of bio-
markers in independent test sets (i.e. not used for discovery)
needs to be performed since most statistical approaches used
for biomarker evaluation assume (i) an even distribution of
features across the data (similar variance in control and
disease groups, and the absence of covariates), (ii) that the
ﬁndings can be generalized and (iii) that an association exists
only with the investigated condition. As these assumptions do
not generally hold in a ‘real world’ setting, most biomarkers
with promising initial results have less promising results in in-
dependent data sets [26]. CKD273 has previously been vali-
dated only in a number of single-centre settings [10–13, 27].
Here we investigated the stability of the CKD273 classiﬁer
for the ﬁrst time in a multicentre setting using prospectively
collected samples. We analysed 165 samples of T2D patients
from 9 different centres. Although sample collection is de-
scribed for each centre in a standardized sampling protocol,
minor differences in sample collection and handling and in
the patient population are expected. In addition, differences in
diet and lifestyle, e.g. in different countries, may impact on the
urinary proteome. However, all of these differences did not
modify the performance of the CKD classiﬁer, which was
found to be similar between the centres, resulting in a consist-
ently high AUC value of 0.89–1.00. Therefore, the present
study complements previous single-centre studies employing
the classiﬁer either focusing on the detection of CKD [10, 27]
F IGURE 2 : Classiﬁcation results of the T2D patient cohort. (A) Classiﬁcation of all T2D patients based on the CKD273 score divided per
centre. The scores of patients with macroalbuminuria or/and eGFR < 45 mL/min/1.73 m2 (cases) are marked in gray and the scores of patients
with normalbuminuria and eGFR > 60 mL/min/1.73 m2 (controls) are marked in black. The diagnosis cut-off of 0.343 is also shown. The centre
number is given on the x-axis (Table 1). (B) Combined ROC curve for the CKD273-based prediction of all T2D patients (n = 165, AUC = 0.95).
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or predicting progression of disease [11–13]. The data demon-
strate that the CKD273 classiﬁer is robust and can be applied
to samples shipped to a central laboratory from different
centres. Importantly, we ascertained that the use of different
sample containers had no effect on the performance of the
CKD273 classiﬁer.
Additional basic issues, including temperature stability, freeze/
thaw stability, post-preparation stability, reproducibility, inter-
mediate precision and time course, have been studied for the
CKD273 classiﬁer, and have previously been described [10]. The
relative intra- and inter-assay standard deviation of the classiﬁer
was below 7 and 10%, respectively [10]. Further technical valid-
ation of CKD273 included assessment of in vivo drug interference
and inter-laboratory variability and resolution, mass accuracy
and amplitude variability of individual peptides. These treatment
interference experiments showed no signiﬁcant modiﬁcation of
the classiﬁer [28]. To address the inter-laboratory variability, the
same 86 samples (45 cases and 41 controls) were analysed in
three different laboratories in Germany, France and the UK. The
individual results were correlated with each other and resulted in
correlation coefﬁcients of 0.881–0.904 [28]. The results of the
current study demonstrate that CE/MS-based urinary proteome
analysis can provide robust and accurate results when applied in
multiple clinical centre studies.
Although we observed high accuracy in the classiﬁcation of
DN (AUC of 0.95), we also recorded a total of 10 false-positive
and 8 false-negative classiﬁcations among the T2D case and
control samples. From four of the apparently false-positive pa-
tients (i.e. controls classiﬁed as cases), follow-up data were
available. One of the apparently false-positive controls devel-
oped microalbuminuria, and one developed macroalbuminur-
ia after 1 year follow-up. The other two false-positive patients
did not develop any sign of DN within the observation period
(8 months – 1 year). These data indicate that the apparent
false positives may in fact be true positives, but at an early stage
of disease that is detectable by CKD273, but not based on albu-
minuria [12]. These observations are preliminary, need to be
expanded to a longer observation period for all patients, but
indicate that the results may, at least in part, be due to the
prognostic capabilities of the classiﬁer as previously suggested
[11–13, 28].
We also investigated the distribution of individual CKD
biomarkers in the single centres. As the cohort size in the
single centres was signiﬁcantly smaller (generally less than one
tenth) than in the study for development of CKD273, we did
not expect to conﬁrm each biomarker. In addition, we did not
observe each of the 273 CKD biomarkers in this cohort of dia-
betic patients, since for the deﬁnition of the 273 CKD biomar-
kers, patients with different CKD aetiologies were used, not
only patients with DN [10]. Therefore, in the complete bio-
marker set of peptides included in CKD273, peptides speciﬁc
to, e.g. IgA-nephropathy, focal segmental glomerulosclerosis,
membranous glomerulonephritis, or ANCA-associated vascu-
litis, are represented. As these are not associated with DN, they
are not expected to be validated in this study.
As expected, the correlation of individual biomarkers with
CKD was lower than the correlation of the biomarker model
with CKD, further supporting the application of a composite
biomarker for the identiﬁcation of complex diseases such as
DN. When all data were combined, the majority of the 273
CKD markers could be veriﬁed in this combined multicentric
cohort of diabetic patients. The most consistent biomarkers
were fragments of alpha-1-antitrypsin, collagen alpha-1 (I) and
(III), serum albumin, uromodulin, alpha-2-HS-glycoprotein,
sodium/potassium-transporting ATPase gamma, polymeric-
immunoglobulin receptor and transthyretin. We hypothesize
that serum albumin and transthyretin are most likely derived
from the circulation, while the different collagen fragments
F IGURE 3 : Validation of the individual 273 CKD biomarkers in the T2D cohort. Veriﬁcation of the CKD biomarkers using all data of T2D pa-
tients (n = 165). Number and names of 67 validated (P < 0.05) protein fragments of the 100 most signiﬁcant CKD biomarkers are shown.
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most likely originate from the kidney. The increased urinary
excretion of alpha-1-antitrypsin by patients with CKD has
already been reported [29–32].
The increased urinary abundance of circulating peptides may
reﬂect structural damage to the glomerular ﬁltration barrier and/
or impaired tubular absorption, which is well known to occur in
CKD [10]. In the current study, all fragments of alpha-1-anti-
trypsin, serum albumin, uromodulin, alpha-2-HS-glycoprotein,
sodium/potassium-transporting ATPase gamma, polymeric-im-
munoglobulin receptor and transthyretin, included in the 100
most signiﬁcant markers from the Good et al. study [10], were
veriﬁed. The number of consistent collagen alpha-1 (I) fragments
was also high, but not all of the collagen alpha-1 (I) fragments in-
cluded in the top 100 CKD273 marker set were replicated. These
results also support the hypothesis that collagen degradation is
signiﬁcantly reduced in DN, resulting in accumulation of colla-
gen in the kidney [33]. The accumulation of collagen results in ﬁ-
brosis, a well-known hallmark of CKD [34]. The stability among
the different centres in circulation- versus kidney-derived
proteins such as collagens suggests that disturbances in the glom-
erular ﬁltration barrier or tubular reabsorption may be earlier
and more general events in the establishment of DN than albu-
minuria. This supports the hypothesis of a common pathway for
the development of DN initiated by impaired glomerular ﬁltra-
tion, leading to protein overload into glomerular and tubular epi-
thelial cells in later stages to ﬁbrosis [35, 36].
In summary, the results presented in this study and previ-
ous data obtained in the validation process of CKD273 set the
stage for the PRIORITY trial and demonstrate the suitability
of the classiﬁer to be used in such a multicentre study to select
patients for intervention, aiming at implementing the ﬁrst
steps towards personalized medicine.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.
oxfordjournals.org.
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ABSTRACT
Background. H.P. Acthar® Gel is currently the only Food and
Drug Administration therapy approved for the treatment of
nephrotic syndrome. Active drug ingredients include
structurally related melanocortin peptides that bind to cell
surface G-protein-coupled receptors known as melanocortin re-
ceptors, which are expressed in glomerular podocytes. In
animal models of membranous nephropathy, stimulation has
been demonstrated to reduce podocyte injury and loss. We hy-
pothesized that H.P. Acthar® Gel would improve symptoms of
the nephrotic syndrome in patients with idiopathic membran-
ous nephropathy.
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